Skip to main content

Advertisement

Table 2 Demographic and clinical characteristics at baseline

From: Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease

Characteristics Control subjects (n = 58) MCI-MCI (n = 27) MCI-AD (n = 28) AD-AD (n = 28) p Value
Sex, M/F, % 32/68 56/44 42/58 50/50  
Age at examination, yearsa 67 (57–77) 64 (53–78) 64 (56–71)b 64 (54–78)c 0.0016
MMSE scorea 30 (28–30) 28 (25–30)d 27 (23–29)d 23 (16–27)d < 0.0001
APOE ε4 status (−/−, +/−, +/+) 32, 19, 0 7, 3, 7 5, 8, 11 5, 16, 7  
CSF Aβ42, pg/mLa 970 (499–1674) 647 (173–1065)d 494 (283–1060)d 460 (212–1092)d < 0.0001
CSF Aβ40, pg/mLa 17,134 (11,152–40,851) 12,554 (3553–31,343)c 15,419 (8021–23,258) 15,397 (6008–29,090) 0.0056
CSF t-tau, pg/mLa 269 (137–1314) 280 (98–1057) 533 (163–2325)d 669 (222–1540)d < 0.0001
CSF p-tau, pg/mLa 53 (33–135) 54 (16–131) 87 (37–169)d 93.0 (36–157)d < 0.0001
  1. Abbreviations: AD Alzheimer’s disease, APOE Apolipoprotein E, 42 Amyloid-β 1–42, CSF Cerebrospinal fluid, MMSE Mini Mental State Examination, p-tau Phosphorylated tau, t-tau Total tau, AD-AD Patients diagnosed with Alzheimer’s disease at inclusion, 40 Amyloid-β 1–40, MCI-AD Patients with mild cognitive impairment who developed Alzheimer’s disease, MCI-MCI Patients with mild cognitive impairment that remained unchanged over 24 months
  2. Sex is presented as percentage male vs female; age at inclusion to the study, MMSE scores, t-tau, p-tau, Aβ42 and Aβ40 levels are presented as median with range. Statistical significance for differences in MMSE scores and levels of CSF biomarkers upon pairwise comparison of control subjects with the MCI-MCI, MCI-AD and AD-AD groups is presented after Bonferroni correction (n = 6). APOE ε4 genotype status is presented as null (−/−), heterozygous (+/−) and homozygous (+/+). p Value is reported for non-parametric analysis of variance among groups by Wilcoxon/Kruskal-Wallis test
  3. aMedian (minimum–maximum)
  4. bp < 0.05
  5. cp < 0.01
  6. dp < 0.001